Specifically, our laboratory has demonstrated that the class I HDAC inhibitor entinostat suppresses Treg cell function, enhances immune responses, and increases the antitumor effect of immunotherapies in preclinical models of kidney and prostate cancer [14, 15, 16, 17]. Here, HDAC9 is linked to prostate cancer.